Nanjing KCI Biotech (KCI) is a preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases and renal diseases. The core competency of KCI stems from our pioneering work and expertise in developing and running specialized animal disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, preliminary toxicology and pathology. Overall, we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirements.